CoCrystal Pharma, Inc. announced that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented on December 1, 2022 at the World Antiviral Congress 2022 underway in San Diego. In November 2022 Cocrystal reported that orally administered CC-42344 showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +3.92% | +5.30% | -7.68% |
May. 01 | Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects | CI |
Mar. 28 | Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.68% | 15.57M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022